| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/27/2003 | WO2003015813A2 Anti-tumor vaccines |
| 02/27/2003 | WO2003015810A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 02/27/2003 | WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | WO2003015792A1 Anti-tumour 2-alkoxyestradiol sulfamates |
| 02/27/2003 | WO2003015790A1 Thiopyrane-4-ones as dna protein kinase inhibitors |
| 02/27/2003 | WO2003015788A1 Methods for treatment of prevention of cancer or neoplastic diseases |
| 02/27/2003 | WO2003015785A1 2h-phthalazin-1-ones and methods for use thereof |
| 02/27/2003 | WO2003015776A1 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity |
| 02/27/2003 | WO2003015773A2 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases |
| 02/27/2003 | WO2003015772A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | WO2003015761A1 Selective estrogen receptor modulators |
| 02/27/2003 | WO2003015759A2 Treatment of hyperproliferative conditions of body surfaces |
| 02/27/2003 | WO2003015757A1 Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| 02/27/2003 | WO2003015755A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | WO2003015717A2 Tyrosine kinase inhibitors |
| 02/27/2003 | WO2003015713A2 Treatment of glial tumors with glutamate antagonists |
| 02/27/2003 | WO2003015712A2 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin |
| 02/27/2003 | WO2003015711A2 Combination motif immune stimulatory oligonucleotides with improved activity |
| 02/27/2003 | WO2003015707A2 Method for treating lung cancers |
| 02/27/2003 | WO2003015705A2 In situ immunization |
| 02/27/2003 | WO2003015703A2 Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| 02/27/2003 | WO2003015698A2 Application of lipid vehicles and use for drug delivery |
| 02/27/2003 | WO2003015697A2 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | WO2003015692A2 Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| 02/27/2003 | WO2003015613A2 Molecular characteristics of non-small cell lung cancer |
| 02/27/2003 | WO2003015608A2 Combination therapy for the treatment of cancer |
| 02/27/2003 | WO2003015606A2 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy |
| 02/27/2003 | WO2003015529A1 A process for tea flower |
| 02/27/2003 | WO2003002123A3 Therapeutic combinations for the treatment of hormone deficiencies |
| 02/27/2003 | WO2003000656A3 Antisense modulation of transforming growth factor beta receptor ii expression |
| 02/27/2003 | WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/27/2003 | WO2002103000A3 Methods for modulating gap junctions |
| 02/27/2003 | WO2002102784A3 2-adamantyl-4,6-diamino-1,2-dihydro-1-aryl-1,3,5-triazine derivatives as cell prolifiration inhibitors |
| 02/27/2003 | WO2002100348A3 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 02/27/2003 | WO2002098399A3 Cancer treatment method and compositions comprising compounds of the ginger family |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002094180A3 Pharmaceutically active isoindoline derivatives |
| 02/27/2003 | WO2002092588A3 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/27/2003 | WO2002092129A3 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 02/27/2003 | WO2002090325A3 Benzazepinone alpha v integrin receptor antagonists |
| 02/27/2003 | WO2002089782A3 Dioxanes and uses thereof |
| 02/27/2003 | WO2002088714A3 Individualization of therapy with antineoplastic agents |
| 02/27/2003 | WO2002088172A3 Pentapeptide compounds and uses related thereto |
| 02/27/2003 | WO2002087472A8 Stent-based delivery of statins to prevent restenosis |
| 02/27/2003 | WO2002083064A3 A method of treating cancer |
| 02/27/2003 | WO2002080851A3 Chimeric vaccines |
| 02/27/2003 | WO2002080845A3 Novel eps8 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002080844A3 Novel bgp compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002079149A3 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 02/27/2003 | WO2002074050A3 Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor |
| 02/27/2003 | WO2002074042A3 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 02/27/2003 | WO2002072542A3 Ph-dependent nmda receptor antagonists |
| 02/27/2003 | WO2002066492A3 Human adrenomedullin-specific antibody, pharmaceutical composition containing same, therapeutic uses thereof |
| 02/27/2003 | WO2002066420A3 Tryptase inhibitors |
| 02/27/2003 | WO2002064590A3 Carboline derivatives |
| 02/27/2003 | WO2002062334A3 Cancer chemopreventative compounds and compositions and methods of treating cancers |
| 02/27/2003 | WO2002060411A3 Process for production of nanoparticles and microparticles by spray freezing into liquid |
| 02/27/2003 | WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| 02/27/2003 | WO2002060374A3 Benz-1,3-azole derivatives and their uses as heparanase inhibitors |
| 02/27/2003 | WO2002056835A3 Anticancer treatment using triptolide prodrugs |
| 02/27/2003 | WO2002055555A3 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002049577A3 Analogues of thiocoraline and be-22179 |
| 02/27/2003 | WO2002046193A3 Heterocyclic ether substituted imidazoquinolines |
| 02/27/2003 | WO2002042436A3 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof |
| 02/27/2003 | WO2002041844A3 Chemotherapeutic composition using nanocrystalline calcium phosphate paste |
| 02/27/2003 | WO2002040477A3 Saframycins, analogues and uses thereof |
| 02/27/2003 | WO2002038105A3 Novel polyamine analog-amino acid conjugates useful as anticancer agents |
| 02/27/2003 | WO2002032378A3 Fusion cells and cytokine compositions for treatment of disease |
| 02/27/2003 | WO2002028865A3 Condensed pyridoindole derivatives |
| 02/27/2003 | WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 02/27/2003 | WO2002020768A3 Caveolin peptides and their use as therapeutics |
| 02/27/2003 | WO2002020767A3 G-csf analog compositions and methods |
| 02/27/2003 | WO2002020000A3 Combined estrogen blockade of the breast with exemestane and raloxifene |
| 02/27/2003 | WO2002008716A3 Method for screening peptides for use in immunotherapy |
| 02/27/2003 | WO2002006308A3 Methods for promoting dendritic cell proliferation or differentiation |
| 02/27/2003 | WO2002001950A3 Transgenic mice containing targeted gene disruptions |
| 02/27/2003 | WO2002000691A3 Polynucleotides and polypeptides encoded thereby |
| 02/27/2003 | WO2001098543A3 Method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 02/27/2003 | WO2001097861A3 Vitronectin receptor antagonist pharmaceuticals |
| 02/27/2003 | WO2001097860A3 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | US20030040640 For use as anti- inflammatory analgesics, in therapy of immune disorders, as anti- cancer and anti-tumor agents, and therapy of cardiovascular disease, skin redness, and viral infection |
| 02/27/2003 | US20030040607 Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof |
| 02/27/2003 | US20030040606 Reducing immunogenicities of immunoglobulins by framework-patching |
| 02/27/2003 | US20030040542 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| 02/27/2003 | US20030040541 Administering bismuth subgallate to inhibit the production of nitric oxide synthases (NOS) |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040535 Tetrazole compounds as thyroid receptor ligands |
| 02/27/2003 | US20030040533 For use as hypoglycaemic and hypolipidaemic agents |
| 02/27/2003 | US20030040527 Having anti-mitotic activity for therapy of cancer |
| 02/27/2003 | US20030040524 Pyrimidine compounds and methods for making and using the same |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040520 For therapy of cancer |
| 02/27/2003 | US20030040517 For use in therapy of pain, fever, inflammation of a variety of conditions and diseases |
| 02/27/2003 | US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 02/27/2003 | US20030040512 Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040508 Altering the conformational equilibrium of the A- ring of a 1 alpha -hydroxylated vitamin D compound to favor a chair conformation for A-ring that presents the 1 alpha-hydroxyl in an axial orientation |
| 02/27/2003 | US20030040507 Pharmaceutical composition comprising ifosfamide and carnitine |